Malignancies Are Caused by Genomic Aberrations {#s1}
==============================================

Genomic instabilities are a hallmark of cancer ([@B62]). Already more than a century ago the causal relationship of chromosomal aberrations and dysfunctional mitosis was suggested ([@B33]; [@B11]), and such research gained significant momentum within the last 20 years with the advent of sequencing technology. For example, in multiple myeloma the relevant genomic aberrations include site-specific mutations, translocations, and gains or losses of parts or whole chromosomes ([@B60]; [@B68]). Some of these aberrations have been shown to be of prognostic relevance, such as deletion in 17p13, translocations between chromosome 4 and chromosome 14, or insertions in 1q21, which are rather associated with worse outcome ([@B25]; [@B61]).

So far, the reasons for the initial genomic instabilities are largely unclear, but it is generally assumed that they simply arise in a stochastic manner. Some passenger mutations may have neutral effects, while others clearly give rise to proliferative advantage, thereby further increasing the risk of malignant transition ([@B12]). This process can be accelerated by dysfunctional DNA repair systems as well as impaired chromosome duplication and segregation during mitosis ([@B19]; [@B78]). Furthermore, inhibition of DNA damage response pathway allows cells to proliferate beyond senescence ([@B30]). Improper chromosome segregation can be caused by telomere shortening, and this may result in chromosome breaks or fusions ([@B4]; [@B38]). There is evidence that the order of genomic events is relevant for tumor progression: Initial chromosome translocations can lead to secondary mutations in genes for DNA replication, repair, or genomic stability, which drastically increase occurrence of tertiary genetic aberrations during further development of the disease ([@B60]; [@B76]). In breast cancer, breast cancer 1 (*BRCA1*) mutations often occur after tumor protein 53 (*TP53*) mutations ([@B57]), because an initial *BRCA1* mutation leads to a cell cycle arrest, which is not in favor of tumor progression ([@B5]). Similarly, the clinical image of myeloproliferative neoplasms was demonstrated to be dependent on the mutation order of ten-eleven translocation 2 (*TET2*) versus janus kinase 2 (*JAK2*): A *JAK2* initial mutation increased the likelihood of presenting with polycythemia vera (as compared to essential thrombocythemia), with an increased risk of thrombosis and an increased sensitivity of *JAK2*-mutant progenitors to ruxolitinib *in vitro* ([@B64]). Taken together, genetic alterations, particularly the mutation order, directly impact the regulation of proliferation, apoptosis, and malignant transformation.

Epigenetic Alterations in Cancer and Clonal Hematopoiesis {#s2}
=========================================================

In contrast to genomic changes, epigenetic aberrations do not involve alterations in the DNA sequence. Dynamic modification of DNA and DNA binding proteins plays a crucial role in the regulation of gene expression, chromatin accessibility, and nuclear architecture ([@B6]; [@B34]; [@B9]). Epigenetic marks comprise, for example, DNA methylation and posttranslational modifications of the N-terminal histone tails, such as acetylation, methylation, ubiquitylation, sumoylation, and phosphorylation ([@B7]). DNA methylation usually occurs at the fifth carbon atom of a cytosine, particularly in the context of cytosine-guanine (CG) dinucleotides, also referred to as a "CpG site" ([@B7]). This process is mediated by DNA methyltransferases (DNMTs), which either maintain existing methylation patterns upon replication (e.g., DNMT1) or create *de novo* patterns (e.g., DNMT3A and DNMT3B) ([@B63]; [@B70]). On the other hand, DNA methylation marks can be indirectly removed by TET enzymes, which oxidize 5-methylcytosine into 5-hydroxymethylcytosine. This modification is then either passively depleted upon DNA replication or actively reverted to cytosine by iterative oxidation and thymine DNA glycosylase (TDG)-mediated base excision repair ([@B48]).

Cancer cells often reveal genome-wide hypomethylation, which may result from mutations in *DNMTs* or *TETs* ([@B46]; [@B69]). At the same time, tumor-suppressor genes can be silenced by site-specific hypermethylation at promoter regions ([@B40]). For example, hypermethylation in *TP53*, cyclin-dependent kinase 4 inhibitor B (*CDKN2B*), glutathione peroxidase 3 (*GPX3*), retinol binding protein 1 (*RBP1*), secreted protein acidic and cysteine rich (*SPARC*), and transforming growth factor beta induced (*TGFBI*) was shown to be associated with the transition from the pre-leukemic phase monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma ([@B36]; [@B43]). Furthermore, hypermethylation in multiple myeloma was shown to be enriched in intronic regions associated with B-cell specific enhancer regions ([@B2]).

So-called "epimutations" resemble specific epigenetic aberrations that mimic genomic mutations, albeit there is no change in the nucleotide sequence. It has been suggested that such epimutations can contribute in a similar way to malignant transformation as genetic mutations ([@B65]; [@B41]). We have previously demonstrated that acute myeloid leukemia (AML) patients frequently display aberrant hypermethylation in *DNMT3A*, which is rather mutually exclusive with genomic mutations in this gene ([@B41]). Mutations as well as epimutations in *DNMT3A* seem to be associated with poor prognosis in AML ([@B41]). Both modifications, mutations and epimutations, may affect alternative splicing of *DNMT3A* ([@B41]), which is important, because the distinct DNMT3A variants have different effects on the DNA methylation pattern ([@B13]). In a recent study, we have demonstrated that knockdown and overexpression of specific transcripts of *DNMT3A* has complementary effects on the DNA methylation pattern, gene expression, and differentiation of hematopoietic progenitor cells---thus, alternative splicing of *DNMT3A* has characteristic epigenetic and functional effects ([@B13]).

Clonal hematopoiesis of indeterminate potential (CHIP) is frequently observed in healthy elderly individuals ([@B12]) and may progress into myeloid and lymphoid malignancies ([@B31]; [@B75]). Notably, the mutations that predominantly occur in clonal hematopoiesis are located in the genes *DNMT3A* and *TET2* ([@B28]; [@B83]). These two genes resemble more than 90% of all mutated genes in CHIP ([@B15]). Overall, mutations in *DNMT3A* are most frequent, whereas *TET2* mutations arise predominantly in older individuals ([@B42]). Furthermore, mutations in *DNMT3A* and *TET2* are frequently observed in AML ([@B51]) and to a lesser degree also in multiple myeloma ([@B20]). These findings support the notion that modulation of DNA methylation patterns plays a central role in initiation of clonal outgrowth and that mutations in epigenetic writers are early key events in the pathogenesis of hematopoietic malignancies ([@B16]; [@B72]).

Usually, clones with mutated driver genes have a competitive advantage over their non-mutated counterparts ([@B1]). In mice it has been demonstrated that hematopoietic stem cells (HSCs) with loss of *Dnmt3a* reveal enhanced self-renewal and repopulation potential, even after 12 rounds of transplantation, far exceeding that of normal HSCs ([@B39]). Mutated HSCs may thus outcompete their native counterparts. While some studies report impaired hematopoiesis ([@B39]; [@B42]), others did not find any significant impact on proliferation or cytopenic effects of either *TET2* or *DNMT3A* mutations in CHIP and found only minor reductions in neutrophils upon *TET2* mutation ([@B15]). Compared to other driver mutations, *DNMT3A* and *TET2* confer a lower risk of progression to AML, but additional mutations, as shown for example for *Npm1* in mice, can drive CHIP to overt malignant transformation, and such genetic changes make diseases detectable years before diagnosis ([@B1]; [@B54]). In general, a higher number of mutations and higher variant allele frequencies have a higher risk of AML progression ([@B1]). Population dynamics studies in healthy individuals indicated that there are hundreds of thousands of stem cells in the body contributing to hematopoiesis, which divide every 2 to 20 months and on average gain 1.2 mutations per division ([@B50]). Therefore, branching sub-clones would be expected over many years during clonal evolution of disease progression.

The relevance of epigenetic writers for clonal hematopoiesis and malignant transformation lays the ground for therapeutic regimen that directly impact the epigenetic landscape. Many novel treatment strategies have been developed for multiple myeloma in the past years ([@B55]), and epigenetic regulators resemble promising targets due to the reversibility of epigenetic marks ([@B3]). Particularly class I and II histone deacetylase (HDAC) inhibitors (such as Varionostat, Panobinostat, and Romidepsin) showed antitumor effects or induced apoptosis *via* the caspase proteolytic pathway ([@B58]; [@B3]). Another promising epigenetic target is the histone methyltransferase enhancer of zeste homolog 2 (EZH2). Inhibition of EZH2 in multiple myeloma cells *in vitro* caused global reduction in H3K27me3 with an antitumor effect in a murine xenograft model ([@B35]). DNA demethylating agents, such as 5-azacytidine, are less extensively studied in multiple myeloma as compared to AML. However, there is some evidence that a decrease in global DNA methylation has some anti-myeloma activity, particularly for therapy-resistant cells ([@B45]; [@B44]), and some studies developed biomarkers to estimate the sensitivity of primary myeloma cells for DNMT inhibitors ([@B59]).

Epigenetic Modifications Can Elicit Genomic Instabilities {#s3}
=========================================================

Heterochromatin, which is usually highly methylated to maintain its condensed structure, as well as lamina-associated domains, almost never contains actively transcribed genes ([@B77]). The chromatin structure is tightly associated with DNA methylation, since specific enzymes that contain a methyl-CpG-binding domain (MBDs) are able to read CpG methylation and recruit chromatin remodelers, such as HDACs ([@B22]). Global hypomethylation, which is observed in various types of cancer, may conversely result in loss of heterochromatin and thereby favor gene rearrangements or chromosomal translocations, due to more frequent homologous recombination events ([@B86]). Furthermore, global depletion of DNA methylation may affect binding of CCCTC-binding factor (CTCF), which regulates chromatin architecture by mediating distal chromosome interactions ([@B80]). Chromatin accessibility is additionally controlled by histone modifications ([@B49]), and cancer cells particularly display a global loss of histone acetylation and overexpression of histone methyltransferases, such as EZH2 ([@B26]; [@B71]). Overexpression of EZH2 has been associated with aberrant mitosis and genetic instability in benign mammary epithelial cells and hinders DNA repair through impairment of RAD51 recombinase repair foci formation at sites of DNA breaks ([@B84]; [@B29]).

DNA methylation not only alters chromatin architecture but also influences genomic integrity by stabilizing transposable elements. Hypomethylation in cancer may therefore result in repeat element-directed recombination ([@B86]). Treatment of lung cell lines with 5-aza-2′-deoxycytidine activated the expression of retrotransposons, such as long interspersed nuclear element 1 (LINE-1) and Alu elements ([@B17]). In addition, hypomethylation of CpG islands can activate nearby oncogenes ([@B24]). On the other hand, focal hypermethylation can indirectly impact genomic stability by silencing of genes that are relevant for genomic integrity ([@B14]) or DNA repair ([@B23]; [@B66]). For example, failure of O^6^-methylguanine repair, e.g., due to hypermethylation in the promotor of the O^6^-methylguanine-DNA methyltransferase (MGMT), results in conversion of G:C to A:T ([@B23]). Last but not least, the cytosine methylation itself can act as an endogenous mutagen, because spontaneous deamination of 5-methylcytosine results in conversion to thymine facilitating point mutations, as observed for most hot-spot mutations in *TP53* ([@B67]). In fact, it was demonstrated that the occurrence of such methylation-induced point mutations largely differs between cancer types, probably because of varying efficiency of DNA repair mechanisms in those tissues ([@B73]). Thus, epigenetic modifications play a crucial role for stabilizing genome integrity, and their dysregulation may facilitate genomic instability ([**Figure 1**](#f1){ref-type="fig"}).
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Do Age-Related Epigenetic Changes Trigger Tumorigenesis? {#s4}
========================================================

There is a growing perception that aging of the organism is reflected by drastic changes in the epigenetic makeup. Upon aging, there is a global loss of DNA methylation, especially at repetitive elements and transposons, which is also seen in cancer cells ([@B10]). Nucleosome occupancy decreases with age ([@B8]), and there is a general decrease in constitutive heterochromatin, which is reflected by a decline of the repressive histone mark H3K9me3 and heterochromatin protein 1 (HP1) ([@B74]). Perhaps the most astonishing age-related epigenetic modification is the finding that a large proportion of CpG sites have highly reproducible DNA methylation changes ([@B82]). Age-associated DNA methylation changes can be observed across diverse cell types and tissues ([@B47]). Due to the high reproducibility, age-associated DNA methylation changes can be used to reliably predict the donor age---known as the "epigenetic clock" ([@B32]; [@B37]; [@B81]). Notably, the rate of epigenetic aging has been linked to life expectancy, indicating that age-associated DNA methylation can also reflect biological aging ([@B56]; [@B53]; [@B85]). It is also striking that age-associated DNA methylation patterns are entirely reset upon reprogramming into induced pluripotent stem cells ([@B27]; [@B81]). However, when it comes to cancer tissue the age predictors fail. In most malignancies the epigenetic clocks are apparently accelerated, whereas they are decelerated in others ([@B52]). This might be attributed to the fact that tumor tissue recapitulates the epigenetic makeup of the tumor initiating cell, whereas age prediction of healthy tissue is based on a cross section of many cells of the normally developing organism. In fact, there is evidence that age-associated DNA methylation patterns are patient-specific and can be used to track clonal growth ([@B21]).

Aging is one of the most relevant risk factors for many types of cancers. Notably, the incidence of cancer diagnosis peaks at different ages for different types of cancer---usually above the age of 50, while, for example, testicular cancer occurs more frequently in younger adults ([@B18]). The reason for this age specificity is not yet fully understood. As indicated above, aging and malignant transformation are to some extent reflected by similar changes in chromatin structure. It is hence conceivable that age-associated epigenetic modifications trigger malignant transformation ([@B79]). In fact, epigenetic clocks in cancer, albeit not related to the donor age, correlate with clinical parameters and overall survival in several types of cancer, indicating that regulation of DNA methylation patterns in age-associated CpGs is relevant for cancer development ([@B52]). Changes in chromatin conformation, which occur commonly at specific ages, might therefore favor tumor-initiating mutations or translocations.

Future Perspectives {#s5}
===================

There is clear evidence that genetic as well as epigenetic aberrations contribute to tumor development---the question is as follows: What comes first? Traditionally, the focus is on tumor-specific mutations, which can be easily tracked throughout disease development. On the other hand, malignant transformation is associated with profound epigenetic shifts, which directly impact chromatin conformation and can thereby impact the genetic sequence, as well. A better understanding of how specific epigenetic alterations might favor occurrence of specific genomic lesions will be important. It might then be possible to address such changes for disease prevention, early diagnosis, or directed therapy. A bottleneck for this research is, however, that the available tumor tissue at the time of diagnosis already reflects genome-wide epigenetic aberrations, which makes it difficult to identify the most relevant epigenetic alterations in early stages of malignancy.
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